Class IA antiarrhythmic drug quinidine was one of the first clinically used compounds to terminate atrial fibrillation and acts as multichannel inhibitor with well-documented inhibitory effects on several cardiac potassium channels. In the mammalian heart, heteromeric assembly of Kir2.1-2.3 channels underlies I K1 current. While a low-affinity block of quinidine on Kir2.1 has already been described, a comparative analysis of effects on other Kir2.x channels has not been performed to date. Therefore, we analyzed the effects of quinidine on wild type and mutant Kir2.x channels in the Xenopus oocyte expression system.
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Introduction
Originally derived from cinchona bark, class IA antiarrhythmic drug quinidine was the first clinical used compound to terminate atrial fibrillation and still is in widespread use today (Grace and Camm, 1998) . Nevertheless, compared with novel class IC antiarrhythmics quinidine has been associated with an increased mortality and unfavorable side effects. Consequently, novel compounds such as class IC and class III antiarrhythmics have been developed and replaced quinidine in the management of atrial fibrillation. Adverse side effects, however, were regularly based on a compromised renal and biliary clearance of digoxin as quinidine competitively inhibits multi drug resistance protein 1 (MDR1) (Doering, 1979; Fromm et al., 1999) . Thus, proarrhythmic side effects of quinidine may be circumvented when its administration is combined with verapamil. Only recently, quinidine has regained clinical interest as one of the most effective agents in the pharmacological management of inherited malignant arrhythmias such as Brugada syndrome, idiopathic ventricular fibrillation and short QT syndromes (Kaufman, 2007; Viskin et al., 2007) . Electrophysiologically, quinidine acts as a broad multichannel blocker with well-documented inhibitory effects on several potassium channels including I to , I Kur , I KATP , I Kr , I Ks , I KACh and I K1 (Tamargo et al., 2004) .
Cardiac inwardly rectifying current I K1 is essential for stabilizing the resting membrane potential of cardiomyocytes (Lopatin and Nichols, 2001) . Several lines of evidence suggest that at the molecular level heteromeric assembly of inwardly JPET #238287 rectifying potassium channels Kir2.1, Kir2.2 and Kir2.3 underlie human cardiac I K1 currents (Schram et al., 2003) . Kir2.1 subunits are abundantly expressed in the entire myocardium and heteromeric Kir2.1/Kir2.2 channels underlie human ventricular I K1 current (Schram et al., 2003) . In contrast, Kir2.3 subunits are stronger expressed in human atria (Wang et al., 1998; Melnyk et al., 2005) .
Cardiac I K1 may constitute a promising target for pharmacological suppression of atrial and ventricular fibrillation. For instance, increased I K1 outward currents due to gain-of-function mutations of Kir2.1 underlie Short-QT-Syndrome Type 3 (SQTS3) (Priori et al., 2005) . These patients are characterized by a shortened QT interval, a strong predisposition for atrial or ventricular fibrillation and can effectively be treated with quinidine. In line with this pathophysiology, it has been demonstrated that familial atrial fibrillation (FAF) is linked to a gain-of-function mutation of Kir2.1 subunits (Xia et al., 2005) . Furthermore, Noujaim et al. (2007) provided direct evidence that increased I K1 currents might stabilize reentrant tachycardias as overexpressing Kir2.1 subunits generated fast and stable rotors in a mouse model.
In silico approaches identified several aromatic residues within the cytoplasmic pore region of Kir2.1 (E224, E299, D255, D259 and F254) to serve as potential binding positions of cationic amphipathic drugs which has been experimentally validated by Ala-scanning mutagenesis (Rodriguez-Menchaca et al., 2008; Noujaim et al., 2010; Lopez-Izquierdo et al., 2011b; van der Heyden et al., 2013) . Noujaim et al. (2011) demonstrated that the inhibitory effect of quinidine on Kir2.1 is mediated by an acute pore block of Kir2.1 subunits involving amino acid JPET #238287 7 residue E224, F254 and D259.
To date, there are no data available regarding other potential mechanisms of action of quinidine or further effects on other Kir2.x subtypes. Therefore, we studied the effects of quinidine on all cardiac wild type and mutant Kir2.x potassium channels in the Xenopus oocyte expression system in order to fully elucidate the molecular properties that may underlie the inhibition of I K1 current by quinidine.
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Methods
DNA constructs and heterologous expression
Kir2.x cDNA constructs were kindly provided by Dr. Barbara Wible (Cleveland, Ohio, USA) and Dr. Carol Vandenberg (Santa Barbara, California, USA).
Complementary mRNA was synthesized from Kir2.x cDNA with the mMESSAGE mMACHINE in vitro transcription kit (Ambion) using T7 Polymerase (Kir2.1 and Kir2.2 constructs) or T3 Polymerase (Kir2.3 constructs). Kir2.x mutants were generated by inverse polymerase chain reaction (PCR) with synthetic mutant oligonucleotide primers using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) as previously described (Karle et al., 2002) . The
Kir2.x-Kir2.y hetero-concatemers ( Fig. 1 ) used in this study were kindly provided by Dr. Regina Preisig-Müller (Marburg, Germany). All mutations and DNA constructs were confirmed by sequencing (SeqLab Goettingen, Germany).
Using a Nanoject automatic injector (Drummond, Broomall, USA) 50 nl per oocyte of cRNA (50 to 500 ng/μl) was injected into stage V and VI defolliculated oocytes. Experiments were performed 1 to 3 days after injection. All experiments performed in this study are in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85-23, revised 1996) .
Electrophysiology and data analysis
Currents were recorded using the two-microelectrode voltage-clamp technique in
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Xenopus laevis oocytes using a commercially available amplifier (Warner OC-725A, Warner Instruments, Hamden, USA) and pCLAMP software (Axon Instruments, Foster City, USA) for data acquisition and analysis. Data were lowpass filtered at 1 to 2 kHz (−3 dB, four-pole Besselfilter) prior to digitalization at 5 to 10 kHz. During the experiments no leak subtraction was performed. Statistical data are presented as mean ± S.E.M. In all figures, n represents the number of cells recorded. Statistical significance was evaluated using Student's t test. For more than 2 groups analysis of variance (oneway ANOVA) was used instead.
Differences were considered to be significant if the p value was <0.05. 
Solutions and drug administration
Voltage clamp measurements of Xenopus oocytes were performed in a K + solution containing (in mM) 5 KCl, 100 NaCl, 1.5 CaCl 2 , 2 MgCl 2 , and 10 HEPES.
The pH of this solution was corrected to 7.4 with 1 M NaOH. Electrodes were filled with 3 M KCl solution. All measurements were carried out at room temperature (20 °C). Xenopus oocytes were incubated in the drug solution.
Recordings were made prior to incubation and 30 min afterwards. Quinidine (Sigma-Aldrich, Steinheim, Germany) was diluted in DMSO to obtain a 100 mM JPET #238287 stock solution and stored at −20 °C. Aliquots of the stock solution were dissolved in the bath solution to the desired concentrations on the day of the experiments.
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Results
Quinidine inhibits Kir2.3 currents
We initially characterized the effects of quinidine on homomeric Kir2.3 subunits.
Channels were heterologously expressed in Xenopus laevis oocytes and currents were recorded using the voltage-clamp technique. In order to measure
Kir2.x currents, a standardized voltage protocol was applied. From a holding potential of -80 mV, 400 ms test pulses ranging from -120 mV to +40 mV were applied in 10 mV increments. Inward current amplitudes at -120 mV were used to quantify inhibitory effects, unless stated otherwise. In Figure 2 representative current traces under control conditions ( Fig. 2A ) and after 30 minutes of incubation with 1 mM quinidine ( Fig. 2B ) are shown. The corresponding currentvoltage (IV) curves are shown in Fig. 2C . Under control conditions we observed a slight current run-up by 9 ± 5.9 % (n=7, data not shown) as previously described (Karle et al., 2002) . Dose-response curves were obtained accordingly. Relative effects of quinidine at concentrations ranging from 5 μM to 1 mM were compared in Xenopus oocytes heterologously expressing Kir2.3 channels and yielded an IC 50 of approximately 72 µM (n=4-16, Fig. 2D ).
Onset and wash-out of the inhibitory effect of quinidine on Kir2.x subunits were investigated using a repetitive voltage clamp protocol at start-to-start intervals of 30 seconds over a time period of 45 min. Starting from a holding potential of -80 mV test pulses to -120 mV and -110 mV for 400 ms were applied to elicit large inward currents. Relative inhibition of Kir2.3 currents during wash-in and wash-JPET #238287
out of quinidine at a concentration of 100 μM are shown in Fig. 2E and Fig. 2F , respectively. Onset of block was slow and approximated steady-state conditions after 45 min (32.8 ± 2.4 % of initial current amplitudes, n=10). Correspondingly, recovery from inhibition was also slow. Even after 45 min of reperfusion with bath solution the current block still persisted as seen in Fig. 2F (71.9 ± 6.3 % of initial current amplitudes, n=10 (Schram et al., 2003) . In order to minimize random association artefacts of coinjected subunits, we solely injected mRNA of hetero-concatemeric Kir2.x-2.y channels ( Fig. 1 ) as previously described (Preisig-Muller et al., 2002) . Under control conditions, Kir2.1-2.2, Kir2.1-2.3 and Kir2.2-2.3 currents increased by 13.6 ± 5.4 %, 18 ± 7 % and 16.6 ± 2.6 %, respectively (n=4 each, data not shown). IV curves of representative current recordings before and after 
Comparison of maximum inhibitory effects of quinidine on Kir2.x channels
The maximum subunit-specific and relative inhibition of Kir2.x or Kir2.x-2.y currents at supramaximal concentrations of quinidine are listed in Table 1 . In comparison, Kir2.3 currents were blocked to the greatest extent, followed by Kir2.2 and Kir2.1 currents. The effects of quinidine on Kir2.x-2.y heteroconcatemers were far less pronounced. Hetero-concatemeric channels containing the Kir2.3 subunits, however, were prone to a greater block when compared to Kir2.1-2.2 hetero-concatemers.
Inhibition of Kir2.x currents by quinidine is voltage-independent
In order to examine whether quinidine inhibits Kir2.x currents in a voltagedependent manner, inhibitory effects were compared at voltages ranging from -120 mV to 0 mV. Inhibitory effects between -80 and -60 mV were excluded from the analysis due to small current amplitudes. We found that the inhibition of Kir2.x currents by quinidine is not significantly different at the analyzed voltages ( Fig. 5 ). Relative current inhibition by 1 mM quinidine ranged from 72.7 ± 8.6 % at -50 mV to 50.6 ± 9.7 % at 0 mV in Kir2.2 currents (n = 6) and 64.5 ± 7 % at -50
This article has not been copyedited and formatted. The final version may differ from this version. JPET #238287 mV to 45.3 ± 17.3 at -20 mV in Kir2.1 currents (n = 4). The relative inhibitory effect of 0.1 mM quinidine on Kir2.3 channels was 68.2 ± 4.2 % at -50 mV and 59.5 ± 2.9 % at -100 mV (n = 7), respectively.
Functional significance of the cytoplasmic pore domain for the inhibitory effects of quinidine
Several negatively charged amino acid residues within the cytoplasmic pore domain of Kir2.1 (E224, F254, and D259) have been associated with an acute block by quinidine (Noujaim et al., 2011 respectively. Also, all studied Ala-mutated Kir2.3 subunits exhibited significantly reduced effects of quinidine, resulting in relative current reductions by 33.9 ± 1.4 % (n=6) in Kir2.3 E216A and 45.1 ± 2.7 % (n=6) in Kir2.3 D247A and in a current increase of 0.07 ± 2.6 % (n=4) in Kir2.3 D251A and 2.3 ± 2.9 % (n=6) in Kir2.3 E291A channels. Interestingly, only mutation D260A altered the effect on Kir2.2 channels with a current increase of 11.5 ± 5.6 % (n=5) after quinidine application (Fig. 7B) .
PIP 2 -mediated inhibition of Kir2.x subunits by quinidine
Glycerophospholipid PIP 2 is essential for membrane-associated signaling. As an important cofactor for channel function and lipid rafts (Suh and Hille, 2008) , it has previously been recognized to participate in high-affinity interactions with inwardly rectifying ion channels and particularly with Kir2.1 subunits (Rohacs et al., 2003; Logothetis et al., 2007 (Xie et al., 2008) and compared the extent of quinidine-mediated blocks as shown in Figure 8 .
This article has not been copyedited and formatted. The final version may differ from this version. µM quinidine as the wild-type current reduction of 18.2 ± 3.8% (n=5) is further increased to 68.9 ± 3.3% (n = 6) and 31 ± 1.1% (n =5), respectively. In contrast, the inhibitory effect of 100 µM quinidine in Kir2.3 wild-type channels (58.6 ± 1.9%, n=16) was completely abolished in Kir2.3 I214L channels with a total current increase of 9.2 ± 3.6 % (n=7).
This article has not been copyedited and formatted. The final version may differ from this version. Chronic atrial fibrillation, chronic AV block and ischemic heart disease are linked to complex regional changes in I K1 /Kir2.x expression profiles (Mustroph et al., 2014) . It has been shown that the increased expression of Kir2.1 contributes to reentrant tachycardias by stabilizing high frequency atrial and ventricular rotors (Noujaim et al., 2007; Girmatsion et al., 2009; Sekar et al., 2009) . Interestingly, the inhibition of I K1 might constitute an effective therapeutic approach to the treatment of reentrant arrhythmias (Warren et al., 2003; Pandit et al., 2005; Kharche et al., 2014) .
However, I K1 dysfunction as a result of chronic heart failure or LQTS has been recognized to destabilize the resting membrane potential of cardiomyocytes and increase their susceptibility for tachyarrhythmias. Furthermore, animal studies provide evidence that pulmonary vein cardiomyocytes exhibit reduced I K1 and Kir2.3 current densities (Ehrlich et al., 2003; Melnyk et al., 2005) , which may at least partly explain their increased arrhythmogenic potential (Cherry et al., 2007) .
Quinidine was the first antiarrhythmic drug used clinically to terminate atrial fibrillation. As a multichannel blocker, quinidine may display a favorable electrophysiological profile by normalizing the effective refractory period while experimentally to be crucial for the inhibitory effect of quinidine (Noujaim et al., 2011 ). Here we demonstrate that, analogously to chloroquine, amino acid residue E299 is involved in the quinidine-mediated inhibition of Kir2.1 channels.
Additionally, the effect of quinidine on Kir2.2 and Kir2.3 channels was evaluated.
Increased I K1 density in patients with chronic atrial fibrillation (Bosch et al., 1999; Workman et al., 2001; Zhang et al., 2005) Kir2.2 currents was fully reversed and it is intriguing to speculate that this observation might be due to fewer binding sites of quinidine and/or weakened interaction of the drug within the channel pore. Nevertheless, the significance of homomer-specific inhibiting kinetics in vivo is questionable considering the low myocardial expression of Kir2.2 subunits on the one hand and the heteromeric nature of human I K1 on the other (Wang et al., 1998; Schram et al., 2002; Melnyk et al., 2005) . In line with these considerations Salata and Wasserstrom (1988) were able to demonstrate that quinidine inhibits canine I K1 currents irreversibly for a period of 45 min. JPET #238287 channels but also earlier reports from animal models suggesting a voltageindependent I K1 block (Salata and Wasserstrom, 1988) . We here provide evidence that endogenous polyamines and quinidine mediate Kir2.x current blocks by interacting with the same residues that line the functional channel pore (Baronas and Kurata, 2014) . Contrary to polyamines, quinidine, however, inhibits
Kir2.x subunits in a voltage-independent manner. This discrepancy may suggest an additional mode of action by which quinidine can facilitate current inhibition.
Considering the subunit-specific sensitivities and kinetics, we hypothesized a combined mechanism for Kir2.x inhibition by quinidine involving direct pore block of the permeation pathway and additional inhibition by interference with PIP 2 -mediated channel stabilization. To validate this hypothesis, we generated previously described Kir2.x mutants with altered PIP 2 affinities (Xie et al., 2008) .
We noticed that high PIP 2 affinities (Kir2.3 I214L) correlate with smaller inhibitory effects. Inversely, channels interacting weakly with PIP 2 (Kir2.1 K182Q and L221I) are prone to a strong inhibitory effect. These data suggest that quinidine inhibits Kir2.x channels by a combined mechanism involving direct pore block and impaired open channel gating by PIP 2 -interference. Although concordant changes in Kir2.1 K182Q/L221I and Kir2.3 I214L currents might suggest that the intrinsic affinity in these channels towards quinidine is unaltered, we acknowledge the fact that these data are obtained at single concentrations. As recordings of native I K1 in cardiomyocytes require pharmacological inhibition of other ion channels, non-specific interactions with intrinsic posttranslational pathways cannot be excluded and are a general concern when interpreting native electrophysiological data. However, it has been demonstrated that quinidine blocks human atrial I K1 currents in a voltage-dependent manner with IC 50 ranging from 4.1-42.6 μM (Nenov et al., 1998) . Noujaim et al. (2011) reported that quinidine inhibits Kir2.1 in mammalian cells in a dose-dependent JPET #238287
manner with an IC 50 of 57 μM, being approximately 6-fold lower than our result from Xenopus oocytes. In humans, antiarrhythmic plasma concentrations of quinidine fall within the range of 2-5 μg/ml corresponding to 6-15 μM (Fremstad et al., 1979; Yang et al., 2009 ) and may even be higher in patients with an individual susceptibility based on renal or hepatic dysfunction, drug interactions, sex, age and pharmacogenomics. Thus, on the data presented here, we hypothesize that an antifibrillatory I K1 block within therapeutic plasma concentrations may primarily be based on the compound's predominant influence on atrial Kir2.3 subunits. In conjunction with other highly sensitive atrial-specific potassium currents like I to , I Kur and I KACh (Tamargo et al., 2004) , quinidine may exhibit a favorable pharmacological profile for the suppression of supraventricular tachyarrhythmias mainly by prolonging refractory periods in human atria.
In the present study we characterized the molecular basis of quinidine's inhibitory effects on human Kir2.x channels. We found that quinidine exerts differential effects on Kir2.x channels with the highest affinity towards Kir2.3 subunits.
Inhibition of Kir2.x channels is mediated by joint modes of action involving direct cytoplasmic pore block and impaired channel gating by interference with PIP 2 stabilization. These data add to the understanding of the antifibrillatory efficacy of quinidine and may contribute to the development of new antiarrhythmic I K1
antagonists.
This article has not been copyedited and formatted. The final version may differ from this version. Kir2.x-2.y hetero-concatemers were generated by concatenating the mRNA of different Kir2 subunits. C-terminal domains of Kir2.x subunits were fused to the N-Terminus of Kir2.y subunits (Preisig-Muller et al., 2002) . Corresponding hetero-concatemeric Kir2.x-2.y constructs were heterologously expressed in the oocyte expression system. For a functional channel pore the association of two hetero-concatemers is required. were excluded from the analysis due to small and unrepresentative amplitudes.
Relative current block of Kir2.x channels did not show significant differences in the analyzed voltage range (n=4-7). Inhibitory effects of quinidine were significantly reduced in all Kir2.1 (A) and Kir2.3 pore mutants (C). Interestingly, Kir2.2 channels differed from these patterns. As shown in panel B only in Kir2.2 D260A mutants the inhibitory effect was significantly altered compared to wild-type channels with a current increase of 11.5 ± 5.6 % (n=5). Quinidine concentration used for Kir2.1, Kir2.2 and Kir2.3 pore mutants were 1 mM, 0.5 mM and 0.1 mM, respectively. Channel mutants which have less affinity to endogenous PIP 2 were significantly more sensitive to the inhibitory effect of 200 µM quinidine (68.9 ± 3.3 %, n=6 for Kir2.1 K182Q and 31 ± 1.1 %, n=5 for Kir2.1 L221I) compared to Kir2.1 wild-type channels (18.2 ± 3.8 %, n=5). Kir2.3 I214L enhances the affinity to PIP 2 and the effects of quinidine on these channels were similar to those under control conditions.
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